Journal of AdvancedMedical and Dental Sciences Research

Background: The present study was conducted for evaluating the efficacy of Dorzolamide 2 percent timolol 0.5 percent fixed combination therapy in patients of primary open angle glaucoma. Materials & methods: The present study was conducted on 20 patients of POAG attending the outpatient Department of Ophthalmology. Fixed drug combination of Dorzolamide2%/ Timolol 0.5% (DTFC) dosed twice daily at a difference of 12 hours. All the patients were instilled 1 drop of DTFC ophthalmic solution into study eye twice daily for 6 weeks. Patients was then be called for follow up at 2nd week, 4th week and 6th week during the study period and IOP was recorded. The eye that was affected was considered as the study eye. Patients having bilateral POAG were treated for both eyes, but only the one eye fulfilling the inclusion criteria was taken as the study eye. IOP readings were taken from the study eye with the Goldmann applanation tonometer (GAT) at each visit. All the results were analysed by SPSS software Results: Mean IOP at visit 1, visit 2, visit 3 and visit 4 was 27.23 mm of Hg, 17.26 mm of Hg, 16.72 mm of Hg and 15.33 mm of Hg respectively. Mean percentage reduction at visit 1, visit 2 and visit 3 was 36.49 percent, 38.59 percent and 43.7 percent respectively.Conjunctival Hyperemia, eye irritation and taste perversion were seen in 20 percent, 5 percent and 5 percent of the patients respectively. Conclusion: The fixed combination of brinzolamide and timolol has been shown to be efficacious and the added utility of providing two medications in one formula may improve patient compliance with the medication.